All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Current and Future Perspectives for Bispecific Antibodies in Multiple Myeloma: Learnings from 2023

with Sagar Lonial, Naresh Bumma, Amrita Krishnan, and Sergio Giralt

Monday, March 11, 2024 | 8:00 am EST

This independent educational activity is supported by Janssen. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.

  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2021-02-20T09:47:21.000Z

ASH 2020| Practice-changing and breakthrough abstracts in multiple myeloma

Bookmark this article

Did you miss ASH 2020? The Multiple Myeloma Hub attended the virtual 62nd ASH Annual Meeting & Exposition, December, 5–8 2020, and has developed two resources in collaboration with our Steering Committee on the abstracts presented regarding multiple myeloma (MM) that could impact your clinical practice in the near future.

In the first downloadable resource, 'practice-changing abstracts', you will find comments from the Multiple Myeloma Hub Steering Committee members about the role of autologous stem cell transplant in the era of novel agents, and the latest updates on new combinations and therapy-sequencing strategies to achieve deeper and more durable responses.

ASH 2020 | Practice-changing abstracts in multiple myeloma

If you would like to view the practice-changing abstracts from ASH 2020 and the expert opinions from our Steering Committee, please download the resource below

Download here

Our second resource, 'breakthrough abstracts', covers the most exciting news about monitoring MM with less-invasive techniques and promising alternative targets to treat refractory disease. Discover underlying resistance mechanisms that could help to early identify relapse or fundament new drug combinations. Find here, the initial results obtained with novel targeted agents and the latest about BCMA-directed immunotherapies (bispecific antibodies and CAR T-cells) in clinical development.

ASH 2020 | Breakthrough abstracts in multiple myeloma

If you would like to view the breakthrough abstracts from ASH 2020 and the expert opinions from our Steering Committee, please download the resource below

Download here

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox